The term ‘receptorome’ is now being used to describe receptors, ion channels and transporters in the human genome that are potential drug targets. These proteins comprise a considerable fraction of the human genome, and include the G protein-coupled receptors, which are the targets for many medications. In this review, we summarize recent advances in the field, including the concept that the ultimate goal of drug discovery may not be the development of highly selective single-target drugs, the idea that potential side-effects can also be the goal of multi-target drug screening, and a discussion of the application of computational screening and public domain databases available to interested investigators.
Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C, and Weiden P J (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry156: 1686–1696
2.
Armbruster B N, Roth B L (2005) Mining the receptorome. J Biol Chem280: 5129–5132
3.
Aronov A M, Goldman B B (2004) A model for identifying HERG K+ channel blockers. Bioorg Med Chem12: 2307–2315
4.
Bains W, Basman A, White C (2004) HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog Biophys Mol Biol86: 205–233
5.
Bajorath J (2001) Rational drug discovery revisited: interfacing experimental programs with bio- and chemo-informatics. Drug Discov Today6: 989–995
6.
Baxter D F, Kirk M, Garcia A F, Raimondi A, Holmqvist M H, Flint K K, Bojanic D, Distefano P S, Curtis R, Xie Y (2002) A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J Biomol Screen7: 79–85
7.
Bock J R, Gough D A (2005) Virtual screen for ligands of orphan G protein-coupled receptors. J Chem Inf Model45: 1402–1414
8.
Bohacek R S, McMartin C, Guida W C (1996) The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev16: 3–50
9.
Cavalli A, Poluzzi E, De Ponti F, Recanatini M (2002) Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J Med Chem45: 3844–3853
10.
Chavkin C, Sud S, Jin W, Stewart J, Zjawiony J K, Siebert D J, Toth B A, Hufeisen S J, Roth B L (2004) Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther308: 1197–1203
11.
De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N (2002) Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf25: 263–286
12.
Dobson C M (2004) Chemical space and biology. Nature432: 824–828
13.
Dowell S J, Brown A J (2002) Yeast assays for G-protein-coupled receptors. Receptors Channels8: 343–352
14.
Ekins S, Crumb W J, Sarazan R D, Wikel J H, Wrighton S A (2002) Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther301: 427–434
15.
Fitzgerald L W, Burn T C, Brown B S, Patterson J P, Corjay M H, Valentine P A, Sun J H, Link J R, Abbaszade I, Hollis J M, Largent B L, Hartig P R, Hollis G F, Meunier P C, Robichaud A J, Robertson D W (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol57: 75–81
16.
Fredriksson R, Schioth H B (2005) The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol67: 1414–1425
17.
Freyhult E, Prusis P, Lapinsh M, Wikberg J E, Moulton V, Gustafsson M G (2005) Unbiased descriptor and parameter selection confirms the potential of proteochemometric modelling. BMC Bioinformatics6: 50-50.
18.
Guo L, Guthrie H (2005) Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Methods52: 123–135
19.
Guthrie H, Livingston F S, Gubler U, Garippa R (2005) A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the IonWorks HTTM System. J Biomol Screen10: 832–840
20.
Hodder P, Mull R, Cassaday J, Berry K, Strulovici B (2004) Miniaturization of intracellular calcium functional assays to 1536-well plate format using a fluorometric imaging plate reader. J Biomol Screen9: 417–426
21.
Iida A, Nakamura Y (2005) Identification of 156 novel SNPs in 29 genes encoding G-protein coupled receptors. J Hum Genet50: 182–191
22.
Iida A, Saito S, Sekine A, Kataoka Y, Tabei W, Nakamura Y (2004) Catalog of 300 SNPs in 23 genes encoding G-protein coupled receptors. J Hum Genet49: 194–208
23.
Kane J M, Barrett E J, Casey D E, Correll C U, Gelenberg A J, Klein S, Newcomer J W (2004) Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry65: 1447–1455
24.
Kiss L, Bennett P B, Uebele V N, Koblan K S, Kane S A, Neagle B, Schroeder K (2003) High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev Technol1: 127–135
25.
Kornienko O, Lacson R, Kunapuli P, Schneeweis J, Hoffman I, Smith T, Alberts M, Inglese J, Strulovici B (2004) Miniaturization of whole live cell-based GPCR assays using microdispensing and detection systems. J Biomol Screen9: 186–195
26.
Kostenis E, Waelbroeck M, Milligan G (2005) Techniques: Promiscuous G alpha proteins in basic research and drug discovery. Trends Pharmacol Sci26: 595–602
27.
Kroeze W K, Sheffler D J, Roth B L (2003b) G-protein-coupled receptors at a glance. J Cell Sci116: 4867–4869
28.
Kroeze W K, Zhang Y, Mangelsdorf D, Roth B L (in press) Schizophrenia Research Kroeze W K, Hufeisen S J, Popadak B A, Renock S M, Steinberg S, Ernsberger P, Jayathilake K, Meltzer H Y, Roth B L (2003a) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology28: 519–526
29.
Lapinsh M, Gutcaits A, Prusis P, Post C, Lundstedt T, Wikberg J E (2002a) Classification of G-protein coupled receptors by alignment-independent extraction of principal chemical properties of primary amino acid sequences. Protein Sci11: 795–805
30.
Lapinsh M, Prusis P, Gutcaits A, Lundstedt T, Wikberg J E (2001) Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. Biochim Biophys Acta1525: 180–190
31.
Lapinsh M, Prusis P, Lundstedt T, Wikberg J E (2002b) Proteochemometrics modeling of the interaction of amine G-protein coupled receptors with a diverse set of ligands. Mol Pharmacol61: 1465–1475
32.
Lapinsh M, Veiksina S, Uhlen S, Petrovska R, Mutule I, Mutulis F, Yahorava S, Prusis P, Wikberg J E (2005) Proteochemometric mapping of the interaction of organic compounds with melanocortin receptor subtypes. Mol Pharmacol67: 50–59
33.
Lipinski C A, Lombardo F, Dominy B W, Feeney P J (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev46: 3–26
34.
Lyne P D (2002) Structure-based virtual screening: an overview. Drug Discov Today7: 1047–1055
35.
Minic J, Persuy M A, Godel E, Aioun J, Connerton I, Salesse R, Pajot-Augy E (2005) Functional expression of olfactory receptors in yeast and development of a bioassay for odorant screening. Febs J272: 524–537
36.
Muller G (2000) Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach. Curr Med Chem7: 861–888
37.
O'Connor K A, Roth B L (2005) Screening the receptorome for plant-based psychoactive compounds. Life Sci78: 506–511
38.
Palczewski K, Kumasaka T, Hori T, Behnke C A, Motoshima H, Fox B A, Le Trong I, Teller D C, Okada T, Stenkamp R E, Yamamoto M, Miyano M (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science289: 739–745
39.
Pausch M H (1997) G-protein-coupled receptors in Saccharomyces cerevisiae: high-throughput screening assays for drug discovery. Trends Biotechnol15: 487–494
40.
Pearlstein R A, Vaz R J, Kang J, Chen X L, Preobrazhenskaya M, Shchekotikhin A E, Korolev A M, Lysenkova L N, Miroshnikova O V, Hendrix J, Rampe D (2003) Characterization of hERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett13: 1829–1835
41.
Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F (2005) QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev25: 133–166
42.
Roth B L, Sheffler D J, Kroeze W K (2004a) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov3: 353–359
43.
Roth B L, Lopez E, Beischel S, Westkaemper R B, Evans J M (2004b) Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther102: 99–110
44.
Roth B L, Baner K, Westkaemper R, Siebert D, Rice K C, Steinberg S, Ernsberger P, Rothman R B (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A99: 11934–11939
45.
Rothman R B, Baumann M H, Savage J E, Rauser L, McBride A, Hufeisen S J, Roth B L (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation102: 2836–2841
46.
Sanguinetti M C, Mitcheson J S (2005) Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci26: 119–124
47.
Setola V, Dukat M, Glennon R A, Roth B L (2005) Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol68: 20–33
48.
Setola V, Hufeisen S J, Grande-Allen K J, Vesely I, Glennon R A, Blough B, Rothman R B, Roth B L (2003) 3,4-methylenedioxymethampheta-mine (MDMA, ‘Ecstasy’) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol63: 1223–1229
49.
Sheffler D J, Roth B L (2003) Salvinorin A: the ‘magic mint’ hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci24: 107–109
50.
Stahura F L, Bajorath J (2002) Bio- and chemo-informatics beyond data management: crucial challenges and future opportunities. Drug Discov Today7: S41–S47
51.
Testai L, Bianucci A M, Massarelli I, Breschi M C, Martinotti E, Calderone V (2004) Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels. Curr Med Chem11: 2691–2706
52.
Venter J C, Adams M D, Myers E W, Li P W, Mural R J, Sutton G G, Smith H O, Yandell M, Evans C A, Holt R A, Gocayne J D, Amanatides P, Ballew R M, Huson D H, Wortman J R, Zhang Q, Kodira C D, Zheng X H, Chen L, Skupski M, Subramanian G, Thomas P D, Zhang J, Gabor Miklos G L, Nelson C, Broder S, Clark A G, Nadeau J, McKusick V A, Zinder N, Levine A J, Roberts R J, Simon M, Slayman C, Hunkapiller M, Bolanos R, Delcher A, Dew I, Fasulo D, Flanigan M, Florea L, Halpern A, Hannenhalli S, Kravitz S, Levy S, Mobarry C, Reinert K, Remington K, Abu-Threideh J, Beasley E, Biddick K, Bonazzi V, Brandon R, Cargill M, Chandramouliswaran I, Charlab R, Chaturvedi K, Deng Z, Di Francesco V, Dunn P, Eilbeck K, Evangelista C, Gabrielian A E, Gan W, Ge W, Gong F, Gu Z, Guan P, Heiman T J, Higgins M E, Ji R R, Ke Z, Ketchum K A, Lai Z, Lei Y, Li Z, Li J, Liang Y, Lin X, Lu F, Merkulov G V, Milshina N, Moore H M, Naik A K, Narayan V A, Neelam B, Nusskern D, Rusch D B, Salzberg S, Shao W, Shue B, Sun J, Wang Z, Wang A, Wang X, Wang J, Wei M, Wides R, Xiao C, Yan C, Yao A, Ye J, Zhan M, Zhang W, Zhang H, Zhao Q, Zheng L, Zhong F, Zhong W, Zhu S, Zhao S, Gilbert D, Baumhueter S, Spier G, Carter C, Cravchik A, Woodage T, Ali F, An H, Awe A, Baldwin D, Baden H, Barnstead M, Barrow I, Beeson K, Busam D, Carver A, Center A, Cheng M L, Curry L, Danaher S, Davenport L, Desilets R, Dietz S, Dodson K, Doup L, Ferriera S, Garg N, Gluecksmann A, Hart B, Haynes J, Haynes C, Heiner C, Hladun S, Hostin D, Houck J, Howland T, Ibegwam C, Johnson J, Kalush F, Kline L, Koduru S, Love A, Mann F, May D, McCawley S, McIntosh T, McMullen I, Moy M, Moy L, Murphy B, Nelson K, Pfannkoch C, Pratts E, Puri V, Qureshi H, Reardon M, Rodriguez R, Rogers Y H, Romblad D, Ruhfel B, Scott R, Sitter C, Smallwood M, Stewart E, Strong R, Suh E, Thomas R, Tint N N, Tse S, Vech C, Wang G, Wetter J, Williams S, Williams M, Windsor S, Winn-Deen E, Wolfe K, Zaveri J, Zaveri K, Abril J F, Guigo R, Campbell M J, Sjolander K V, Karlak B, Kejariwal A, Mi H, Lazareva B, Hatton T, Narechania A, Diemer K, Muruganujan A, Guo N, Sato S, Bafna V, Istrail S, Lippert R, Schwartz R, Walenz B, Yooseph S, Allen D, Basu A, Baxendale J, Blick L, Caminha M, Carnes-Stine J, Caulk P, Chiang Y H, Coyne M, Dahlke C, Mays A, Dombroski M, Donnelly M, Ely D, Esparham S, Fosler C, Gire H, Glanowski S, Glasser K, Glodek A, Gorokhov M, Graham K, Gropman B, Harris M, Heil J, Henderson S, Hoover J, Jennings D, Jordan C, Jordan J, Kasha J, Kagan L, Kraft C, Levitsky A, Lewis M, Liu X, Lopez J, Ma D, Majoros W, McDaniel J, Murphy S, Newman M, Nguyen T, Nguyen N, Nodell M, Pan S, Peck J, Peterson M, Rowe W, Sanders R, Scott J, Simpson M, Smith T, Sprague A, Stockwell T, Turner R, Venter E, Wang M, Wen M, Wu D, Wu M, Xia A, Zandieh A, Zhu X (2001) The sequence of the human genome. Science291: 1304–1351
53.
Weber M, Ferrer M, Zheng W, Inglese J, Strulovici B, Kunapuli P (2004) A 1536-well cAMP assay for Gs- and Gi-coupled receptors using enzyme fragmentation complementation. Assay Drug Dev Technol2: 39–49
54.
Wetterling T (2001) Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf24: 59–73
55.
Wikberg J E, Mutulis F, Mutule I, Veiksina S, Lapinsh M, Petrovska R, Prusis P (2003) Melanocortin receptors: ligands and proteochemometrics modeling. Ann N Y Acad Sci994: 21–26
56.
Wirshing D A, Wirshing W C, Kysar L, Berisford M A, Goldstein D, Pashdag J, Mintz J, Marder S R (1999) Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry60: 358–363
57.
Yan F, Roth B L (2004) Salvinorin A: a novel and highly selective kappa-opioid receptor agonist. Life Sci75: 2615–2619
